Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the …
Biotechnology
US, Waltham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Syndax Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | - | -3.570 | - | 1 | - | -251 | - | 0.04 | - | 0.04 | - | 6 |
| 2017 | -3.0400 | -2.832 | 1 | 1 | -44 | -199 | -43 | 0.05 | -43 | 0.05 | 13 | 6 |
| 2018 | -2.9000 | -2.940 | 2 | 1 | -60 | -206 | -61 | 0.06 | -61 | 0.06 | 15 | 8 |
| 2019 | -2.9200 | -1.825 | 1 | 1 | -73 | -128 | -73 | 0.06 | -75 | 0.06 | 17 | 8 |
| 2020 | -1.8400 | -1.864 | 1 | 1 | -55 | -131 | -55 | 0.06 | -57 | 0.05 | 16 | 8 |
| 2021 | -1.7700 | -2.042 | 1 | 19 | -73 | -143 | -70 | 0.72 | -71 | 0.71 | 22 | 105 |
| 2022 | 0.4800 | -2.531 | 139 | 0.38 | 24 | -178 | 27 | 0.01 | 25 | 0.01 | 25 | 2 |
| 2023 | -2.3700 | -2.945 | 0 | 0 | -143 | -209 | -151 | 0 | -152 | 0 | 33 | 0 |
| 2024 | -2.9800 | -3.482 | 0 | 48 | -209 | -229 | -229 | 1 | -229 | 1 | 66 | 268 |
| 2025 | - | -3.854 | - | 98 | - | -272 | - | 3 | - | 3 | - | 543 |
| 2026 | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |